Today’s Research Reports on Stocks to Watch: Achaogen and Avinger

NEW YORK, NY / ACCESSWIRE / June 27, 2018 / Shares of Achaogen were plummeting in Tuesday trading after the FDA cleared the way for its Zemdri as a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae but issued a complete response letter for the drug as a potential treatment option for blood stream infection. Shares of Avinger were soaring after the company announced a positive initial case experience using the company’s next-generation Pantheris image-guided atherectomy system for the treatment of peripheral artery disease (PAD).

RDI Initiates Coverage on:

Achaogen, Inc.
https://www.rdinvesting.com/report/?ticker=AKAO

Avinger, Inc.
https://www.rdinvesting.com/report/?ticker=AVGR

Achaogen, Inc. shares closed down a little over 20% on Tuesday and hit a new low of $8.73. The big tumble came despite the company’s Zemdri, the trade name for plazomicin, being given approval from the FDA to treat adults with complicated urinary tract infections that include pyelonephritis. Despite the green light, traders were more concerned with the FDA issuing a complete response letter for plazomicin as a potential treatment option for blood stream infection. The FDA said there is inadequate evidence of effectiveness thrown up by the CARE study, a Phase 3 trial that evaluated it for the indication. CEO of the company, Blake Wise, remarked, “The approval of ZEMDRI marks a significant milestone for Achaogen and we are excited to offer healthcare practitioners a new treatment option for patients with certain serious bacterial infections. ZEMDRI is designed to retain its potent activity in the face of certain difficult-to-treat MDR infections, including CRE and ESBL- producing Enterobacteriaceae. Today’s milestone was made possible by our employees, by patients and investigators involved in our clinical trials, and by BARDA, who contributed significant funding for the development of ZEMDRI. This marks an important step in our commitment to fighting MDR bacteria and we are excited to launch ZEMDRI, a much needed once-daily antibiotic.”

Access RDI’s Achaogen, Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=AKAO

Avinger, Inc. shares closed up 15.43% on Tuesday and continued to see even more gains in after-hours trading after the developer of innovative treatments for peripheral artery disease (PAD) announced a positive initial case experience using its next-generation Pantheris image-guided atherectomy system for the treatment of PAD. According to the company’s press release, several physicians have successfully treated over 40 patients in the US across 13 sites with the system. Dr. Glen Schwartzberg, who was the first physician to use both versions of the device in the U.S., remarked, “I am very excited about the outcomes for patients that the next-generation Pantheris has helped me achieve in my initial 10 cases.” Avinger CEO Jeff Soinski commented, “We are very pleased to deliver an enhanced device that will help Dr. Schwartzberg, and other physicians like him, produce better outcomes for patients. Our first US cases confirm many of the design changes incorporated into the next-generation Pantheris have improved performance and durability of the technology. Gaining experience across multiple users in the United States, different physician specialties, and a variety of lesion characteristics further substantiates the results generated with the next-generation device in Europe over the past few months.”

Access RDI’s Avinger, Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=AVGR

Our Actionable Research on Achaogen, Inc. (NASDAQ: AKAO) and Avinger, Inc. (NASDAQ: AVGR) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 503869